Search NLS News

AlzeCure Pharma has received a response from the US Food and Drug Administration (FDA) regarding the preIND application that was submitted prior to the planned phase IIa study with ACD440 in neuropathic pain. ACD440 completed a positive phase Ib study in 2021 and the company now plans to initiate a clinical phase IIa study in […]

Gedea Biotech has successfully completed recruitment of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University NHS Hospitals Trust across 6 UK […]

NLS asked Pam Putz, Managing Director, EBD Group EU, how to make the most out of a digital visit to BIO-Europe Spring and what we should not miss this year. Tell me about your decision to arrange BIO-Europe Spring digitally? “The decision to make BIO-Europe Spring a 100% digital event came from recent renewals of […]

The two companies have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA. CIMZIA’s primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. In 2020 global sales of CIMZIA were 1.8 billion […]

Ulf Ahlfors joins Qlucore from Assa Abloy where he was product manager. “Ulf Ahlfors’ abilities and experience will fit the Qlucore team perfectly in terms of growth in the research area and also in upscaling in the diagnostics area,” says Carl-Johan Ivarsson, CEO of Qlucore. “He has a perfect mix of skills, partly from different […]

The vaccine-induced protection against SARS-CoV-2 infection wanes within a couple of months, but at different speed according to vaccine type, reports scientists from Umeå University. However, protection against severe COVID-19 appears to be better maintained. This is shown in a nationwide, registry-based study performed by researchers at Umeå University that now is published in The […]

The Nordic countries are looking into starting joint vaccine production facilities to be prepared for future pandemics. Last year, Sweden took the initiative for Nordic co-operation, which will map the resources of both public and private companies when it comes to the development and production of vaccines in the Nordic region. “It’s about trying to […]

Until 2021, only researchers based in Denmark were eligible to receive the Novo Nordisk Foundation (NNF)’s grants under the Distinguished Innovator programme, but from 2022 researchers in any Nordic country (Denmark, Finland, Iceland, Norway and Sweden) are eligible. These grants support research within life science and aim to stimulate innovation and entrepreneurship at universities by […]

Swiss-Finnish Aurealis Therapeutics has entered into an exclusive license and collaboration agreement with Xbiome for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for […]

Ultimovacs has completed treatment of the second dose cohort in the Phase I TENDU trial. The study is designed to evaluate the company’s Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer. Encouraging results The Drug Safety Monitoring Board (DSMB), a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns related to the first two dose cohorts. A […]